- Home
- ZIP vs ARVN Comparison
ZIP vs ARVN Comparison
Compare ZIP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- ARVN
- Stock Information
- Founded
- ZIP 2010
- ARVN 2015
- Country
- ZIP United States
- ARVN United States
- Employees
- ZIP N/A
- ARVN N/A
- Industry
- ZIP Diversified Commercial Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ZIP Consumer Discretionary
- ARVN Health Care
- Exchange
- ZIP Nasdaq
- ARVN Nasdaq
- Market Cap
- ZIP 489.6M
- ARVN 456.2M
- IPO Year
- ZIP 2021
- ARVN 2018
- Fundamental
- Price
- ZIP $4.24
- ARVN $7.59
- Analyst Decision
- ZIP Hold
- ARVN Buy
- Analyst Count
- ZIP 5
- ARVN 21
- Target Price
- ZIP $7.40
- ARVN $20.53
- AVG Volume (30 Days)
- ZIP 753.2K
- ARVN 1.8M
- Earning Date
- ZIP 08-11-2025
- ARVN 08-05-2025
- Dividend Yield
- ZIP N/A
- ARVN N/A
- EPS Growth
- ZIP N/A
- ARVN N/A
- EPS
- ZIP N/A
- ARVN N/A
- Revenue
- ZIP $461,827,000.00
- ARVN $426,900,000.00
- Revenue This Year
- ZIP N/A
- ARVN $7.57
- Revenue Next Year
- ZIP $11.97
- ARVN N/A
- P/E Ratio
- ZIP N/A
- ARVN N/A
- Revenue Growth
- ZIP N/A
- ARVN 498.74
- 52 Week Low
- ZIP $4.18
- ARVN $5.90
- 52 Week High
- ZIP $11.25
- ARVN $29.96
- Technical
- Relative Strength Index (RSI)
- ZIP 32.15
- ARVN 48.74
- Support Level
- ZIP $4.47
- ARVN $7.41
- Resistance Level
- ZIP $4.76
- ARVN $8.15
- Average True Range (ATR)
- ZIP 0.24
- ARVN 0.39
- MACD
- ZIP -0.02
- ARVN -0.03
- Stochastic Oscillator
- ZIP 8.00
- ARVN 32.53
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.